前列腺癌
医学
癌症研究
骨髓
骨转移
免疫疗法
癌症
趋化因子
20立方厘米
肿瘤微环境
C-C趋化因子受体6型
癌细胞
免疫系统
间质细胞
内科学
免疫学
转移
趋化因子受体
作者
Youmna Kfoury,Ninib Baryawno,Nicolas Sévère,Shenglin Mei,Karin Gustafsson,Taghreed Hirz,Thomas Brouse,Elizabeth W. Scadden,Anna A. Igolkina,Konstantinos D. Kokkaliaris,Bryan D. Choi,Nikolas Barkas,Mark A. Randolph,John H. Shin,Philip J. Saylor,David T. Scadden,David B. Sykes,Peter V. Kharchenko
出处
期刊:Cancer Cell
[Elsevier]
日期:2021-11-01
卷期号:39 (11): 1464-1478.e8
被引量:124
标识
DOI:10.1016/j.ccell.2021.09.005
摘要
Bone metastases are devastating complications of cancer. They are particularly common in prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy. We seek to define distinct features of the bone marrow (BM) microenvironment by analyzing single cells from bone metastatic prostate tumors, involved BM, uninvolved BM, and BM from cancer-free, orthopedic patients, and healthy individuals. Metastatic PCa is associated with multifaceted immune distortion, specifically exhaustion of distinct T cell subsets, appearance of macrophages with states specific to PCa bone metastases. The chemokine CCL20 is notably overexpressed by myeloid cells, as is its cognate CCR6 receptor on T cells. Disruption of the CCL20-CCR6 axis in mice with syngeneic PCa bone metastases restores T cell reactivity and significantly prolongs animal survival. Comparative high-resolution analysis of PCa bone metastases shows a targeted approach for relieving local immunosuppression for therapeutic effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI